Intercept’s CRL Just Continues Upheaval In NASH

 
• By Joseph Haas

With approval timeline for OCA now thoroughly unclear and Genfit on the ropes, might the top spot in NASH end up with Galmed, AbbVie, Madrigal, Inventiva or Gilead instead?

Drugs question mark
The NASH competition may be wide-open again

More from New Products

More from Scrip